SCHEMBL29629238

SCHEMBL29629238

CCN1CCN(Cc2ccc(NC(=O)Nc3nc(C)c(-c4ccnc(NC)n4)s3)cc2C(F)(F)F)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 5/20 0.60
CDK8 P49336 8/20 0.59
CCNC P24863 5/20 0.59
MAPK14 Q16539 3/20 0.57
MAP3K20 Q9NYL2 3/20 0.57
MAP3K7 O43318 2/20 0.57
MAP4K2 Q12851 2/20 0.57
ABL1 P00519 5/20 0.57
TEK Q02763 3/20 0.57
NTRK1 P04629 2/20 0.57
NTRK2 Q16620 2/20 0.57
KDR P35968 4/20 0.56
SRC P12931 4/20 0.52
MKNK2 Q9HBH9 3/20 0.52
CDK2 P24941 3/20 0.52
BCR P11274 2/20 0.52
MKNK1 Q9BUB5 2/20 0.52
STK10 O94804 2/20 0.52
KIT P10721 2/20 0.52
BRAF P15056 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23068681 1.00 RET (0.60) RETCDK8CCNCMAPK14MAP3K20
SCHEMBL23068646 0.94 CDK8 (0.59) RETCDK8CCNCABL1TEK
SCHEMBL29629218 0.94 CDK8 (0.59) RETCDK8CCNCABL1TEK
SCHEMBL29629256 0.93 RET (0.55) RETCDK8CCNCMAPK14MAP3K20
SCHEMBL23068654 0.93 RET (0.55) RETCDK8CCNCMAPK14MAP3K20
SCHEMBL23068637 0.93 CDK8 (0.58) RETCDK8CCNCMAPK14MAP3K20
SCHEMBL29629205 0.93 CDK8 (0.58) RETCDK8CCNCMAPK14MAP3K20
SCHEMBL23068652 0.93 CDK9 (0.53) RETCDK8CCNCMAPK14MAP3K20
SCHEMBL29629215 0.93 CDK9 (0.53) RETCDK8CCNCMAPK14MAP3K20
SCHEMBL23068640 0.92 CDK8 (0.51) RETCDK8CCNCMAPK14MAP3K20

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740484-B1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-09-11 EP claimed
CN-111757881-B 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents 澳升医药公司 2024-05-07 CN claimed
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-03-23 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 RET 494/4885CDK8 1/4885CCNC 38/4885
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents CDK8, CDK18, CDK9 RET 494/4885CDK8 1/4885CCNC 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.